{"id":28120,"date":"2025-02-26T19:20:52","date_gmt":"2025-02-26T11:20:52","guid":{"rendered":"https:\/\/flcube.com\/?p=28120"},"modified":"2025-02-26T19:20:54","modified_gmt":"2025-02-26T11:20:54","slug":"micurx-pharmaceuticals-sues-medpace-over-breach-of-contract-in-phase-iii-study","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=28120","title":{"rendered":"MicuRx Pharmaceuticals Sues Medpace Over Breach of Contract in Phase III Study"},"content":{"rendered":"\n

Sino-US biotech firm MicuRx Pharmaceuticals Inc. (SHA: 688373<\/a>) has filed a lawsuit against US-based Medpace, Inc. in the Western Division of the United States District Court for the Southern District of Ohio. The suit accuses Medpace of violating contractual obligations and seeks compensation for losses and expenses, including interest up to the judgment date. MicuRx also requests additional remedies deemed fair by the court.<\/p>\n\n\n\n

Background of the Dispute<\/strong>
The legal action stems from a Master Services Agreement signed on January 5, 2022, under which Medpace was engaged as a Contract Research Organization (CRO) to manage MicuRx’s global, multi-center Phase III study for MRX-4 combined with contezolid (MRX-I). However, Medpace failed to meet agreed goals. MicuRx terminated Task Order 1 in December 2023 and requested data return. In early 2024, Medpace sought to terminate Task Order 2 but did not transfer data, infringing MicuRx’s rights.<\/p>\n\n\n\n

Mediation and Data Return<\/strong>
MicuRx applied for a temporary court order to retrieve the data. A mediation agreement was reached in November 2024, with MicuRx providing the required deposit and Medpace returning the data as stipulated.<\/p>\n\n\n\n

Ongoing Litigation<\/strong>
The parties remain deadlocked on other claims. MicuRx’s lawsuit, confirmed by the court on February 24, 2025, seeks compensation for losses. The case has not yet been heard.<\/p>\n\n\n\n

Impact on Clinical Trials<\/strong>
MicuRx stated the lawsuit will not affect its Phase III study for MRX-4\/MRX-I, having replaced the CRO in Q1 2024. The completed Phase III study in China is also unaffected.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Sino-US biotech firm MicuRx Pharmaceuticals Inc. (SHA: 688373) has filed a lawsuit against US-based Medpace,…<\/p>\n","protected":false},"author":1,"featured_media":28123,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7],"tags":[19,3769,279,1102],"class_list":["post-28120","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","tag-cro-cmo-cdmo","tag-medpace","tag-micurx-pharmaceuticals","tag-sha-688373"],"yoast_head":"\nMicuRx Pharmaceuticals Sues Medpace Over Breach of Contract in Phase III Study - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Sino-US biotech firm MicuRx Pharmaceuticals Inc. (SHA: 688373) has filed a lawsuit against US-based Medpace, Inc. in the Western Division of the United States District Court for the Southern District of Ohio. The suit accuses Medpace of violating contractual obligations and seeks compensation for losses and expenses, including interest up to the judgment date. MicuRx also requests additional remedies deemed fair by the court.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=28120\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"MicuRx Pharmaceuticals Sues Medpace Over Breach of Contract in Phase III Study\" \/>\n<meta property=\"og:description\" content=\"Sino-US biotech firm MicuRx Pharmaceuticals Inc. (SHA: 688373) has filed a lawsuit against US-based Medpace, Inc. in the Western Division of the United States District Court for the Southern District of Ohio. The suit accuses Medpace of violating contractual obligations and seeks compensation for losses and expenses, including interest up to the judgment date. MicuRx also requests additional remedies deemed fair by the court.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=28120\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-02-26T11:20:52+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-02-26T11:20:54+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/02\/2602-png.avif\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"540\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=28120#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=28120\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"MicuRx Pharmaceuticals Sues Medpace Over Breach of Contract in Phase III Study\",\"datePublished\":\"2025-02-26T11:20:52+00:00\",\"dateModified\":\"2025-02-26T11:20:54+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=28120\"},\"wordCount\":253,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=28120#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/02\\\/2602-png.avif\",\"keywords\":[\"CRO \\\/ CMO \\\/ CDMO\",\"Medpace\",\"MicuRx Pharmaceuticals\",\"SHA: 688373\"],\"articleSection\":[\"Company\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=28120#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=28120\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=28120\",\"name\":\"MicuRx Pharmaceuticals Sues Medpace Over Breach of Contract in Phase III Study - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=28120#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=28120#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/02\\\/2602-png.avif\",\"datePublished\":\"2025-02-26T11:20:52+00:00\",\"dateModified\":\"2025-02-26T11:20:54+00:00\",\"description\":\"Sino-US biotech firm MicuRx Pharmaceuticals Inc. (SHA: 688373) has filed a lawsuit against US-based Medpace, Inc. in the Western Division of the United States District Court for the Southern District of Ohio. The suit accuses Medpace of violating contractual obligations and seeks compensation for losses and expenses, including interest up to the judgment date. MicuRx also requests additional remedies deemed fair by the court.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=28120#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=28120\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=28120#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/02\\\/2602-png.avif\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/02\\\/2602-png.avif\",\"width\":1080,\"height\":540,\"caption\":\"MicuRx Pharmaceuticals Sues Medpace Over Breach of Contract in Phase III Study\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=28120#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"MicuRx Pharmaceuticals Sues Medpace Over Breach of Contract in Phase III Study\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"MicuRx Pharmaceuticals Sues Medpace Over Breach of Contract in Phase III Study - Insight, China's Pharmaceutical Industry","description":"Sino-US biotech firm MicuRx Pharmaceuticals Inc. (SHA: 688373) has filed a lawsuit against US-based Medpace, Inc. in the Western Division of the United States District Court for the Southern District of Ohio. The suit accuses Medpace of violating contractual obligations and seeks compensation for losses and expenses, including interest up to the judgment date. MicuRx also requests additional remedies deemed fair by the court.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=28120","og_locale":"en_US","og_type":"article","og_title":"MicuRx Pharmaceuticals Sues Medpace Over Breach of Contract in Phase III Study","og_description":"Sino-US biotech firm MicuRx Pharmaceuticals Inc. (SHA: 688373) has filed a lawsuit against US-based Medpace, Inc. in the Western Division of the United States District Court for the Southern District of Ohio. The suit accuses Medpace of violating contractual obligations and seeks compensation for losses and expenses, including interest up to the judgment date. MicuRx also requests additional remedies deemed fair by the court.","og_url":"https:\/\/flcube.com\/?p=28120","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-02-26T11:20:52+00:00","article_modified_time":"2025-02-26T11:20:54+00:00","og_image":[{"width":1080,"height":540,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/02\/2602-png.avif","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=28120#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=28120"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"MicuRx Pharmaceuticals Sues Medpace Over Breach of Contract in Phase III Study","datePublished":"2025-02-26T11:20:52+00:00","dateModified":"2025-02-26T11:20:54+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=28120"},"wordCount":253,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=28120#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/02\/2602-png.avif","keywords":["CRO \/ CMO \/ CDMO","Medpace","MicuRx Pharmaceuticals","SHA: 688373"],"articleSection":["Company"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=28120#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=28120","url":"https:\/\/flcube.com\/?p=28120","name":"MicuRx Pharmaceuticals Sues Medpace Over Breach of Contract in Phase III Study - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=28120#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=28120#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/02\/2602-png.avif","datePublished":"2025-02-26T11:20:52+00:00","dateModified":"2025-02-26T11:20:54+00:00","description":"Sino-US biotech firm MicuRx Pharmaceuticals Inc. (SHA: 688373) has filed a lawsuit against US-based Medpace, Inc. in the Western Division of the United States District Court for the Southern District of Ohio. The suit accuses Medpace of violating contractual obligations and seeks compensation for losses and expenses, including interest up to the judgment date. MicuRx also requests additional remedies deemed fair by the court.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=28120#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=28120"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=28120#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/02\/2602-png.avif","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/02\/2602-png.avif","width":1080,"height":540,"caption":"MicuRx Pharmaceuticals Sues Medpace Over Breach of Contract in Phase III Study"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=28120#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"MicuRx Pharmaceuticals Sues Medpace Over Breach of Contract in Phase III Study"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/02\/2602-png.avif","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/28120","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=28120"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/28120\/revisions"}],"predecessor-version":[{"id":28124,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/28120\/revisions\/28124"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/28123"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=28120"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=28120"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=28120"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}